Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the Mptp mouse model of Parkinson's disease: Focus on endogenous neurorestoration

Current Aging Science

Volumn 6, Issue 1, 2013, Pages 45-55

  L'Episcopo, Francesca ^a   Tirolo, Cataldo ^a   Testa, Nuccio ^a   Caniglia, Salvo ^a   Morale, Maria Concetta ^a   Marchetti, Bianca ^a,b  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Astrocytes; Dopaminergic neurons; Neurodegeneration; Neurogenesis; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AROMATASE; ASCORBIC ACID; BETA CATENIN; CHEMOKINE; CYCLOOXYGENASE 2; DOPAMINE; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOCORTICOID RECEPTOR; GLUTATHIONE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MYELOPEROXIDASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXYNITRITE; PROTEIN S 100; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN; WNT1 PROTEIN;

ADULT STEM CELL; AGING; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; ASTROCYTE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HOMEOSTASIS; HUMAN; MESENCEPHALON; MICROGLIA; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARACRINE SIGNALING; PARKINSON DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STRIATONIGRAL DEGENERATION;

ANIMALS; ASTROCYTES; DOPAMINERGIC NEURONS; HUMANS; INFLAMMATION; MICE; MODELS, NEUROLOGICAL; MPTP POISONING; NERVE DEGENERATION; NERVE REGENERATION; NEUROGENESIS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; VISUAL CORTEX; WNT SIGNALING PATHWAY;

EID: 84882779971     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811306010007     Document Type: Article

References (72)

1. Di Monte DA, Langston JW. Idiopathic and 1-methyl-4phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. In: H Kettenmann and BR Ransom, eds, Neuroglia. Oxford University Press, 1995; Chapter 65: pp.989-97.
2. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: Possible neurochemical mechanisms. Adv Neurol 1993; 60: 140-7.
3. Olanow CW, Shapira AHV, Agid Y. Neurodegeneration and prospects for neuroprotection and rescue in Parkinson's disease. Ann Neurol 2003; 53(Suppl 3): S1-2.
4. Betarbet R, Canet-Aviles RM, Sherer TB, et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitinproteasome system. Neurobiol Dis 2006; 22: 404-20.
5. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 2003; 91: 133-42.
6. Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson's disease. Neurotoxicology 2002; 23: 487-502.
7. Logroscino G. The role of early life environmental risk factors in Parkinson's disease. What is the evidence? Environ Health Perspectives 2005; 113: 1234-8.
8. Marchetti B, Serra PA, L'Episcopo F, et al. Hormones are key actors in gene X environment interactions programming the vulnerability to Parkinson's disease: Glia as a common final pathway. Ann NY Acad Sci 2005; 1057: 296-318.
9. Warner TT, Schapira AHV. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003; 53: S16-25.
10. Morale MC, Serra PA, L'Episcopo F, et al. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006; 138: 869-78.
11. Morale MC, L'Episcopo F, Tirolo C, et al. Loss of Aromatase Cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev 2008; 57(2): 431-43.
12. Morissette M, Al Swedi S, Callier S, Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol 2008; 290: 60-9.
13. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol Disord Drug Targets 2010; 9: 349-72.
14. Chen H, Zhang SM, Herman MA, et al. Non steroidal antiinflammatory drugs and the risk of Parkinson's disease. Arch Neurol 2003; 60:1059-64.
15. Schiess M. Non steroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arc Neurol 2003; 60: 1043-44.
16. L'Episcopo F, Tirolo C, Caniglia S, et al. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroinflamm 2010; 7: 83.
17. L'Episcopo F, Tirolo C, Testa N, et al. Switching microglial harmful phenotype promotes life-long restoration of Substantia Nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice. Rejuvenation Res 2011; 14: 411-24.
18. Langston JW, Forno LS Tetrud J, Reevers AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine exposure. Ann Neurol 1999; 46: 598-605.
19. Langston JW, Sastry S, Chan P, Forno LS, Bolin LM, Di Monte DA. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp Neurol 1998; 154(2): 684-90.
20. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998; 13(2): 221-7.
21. Barcia C, Ferandez-Barreiro A, Poza M, Herrero MT. Parkinson's disease and inflammatory changes. Neurotox Res 2004; 5: 411-8.
22. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008; 29(8): 357-65.
23. Herrera J, Castano A, Venero JL, Cano J, Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000; 7: 429-47.
24. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97.
25. Hoang T, Choi DK, Nagai M, et al. Neuronal NOS and ciyclooxygenase- 2 contribute to DNA damage in a mouse model of Parkinson Disease. Free Radic Biol Med 2009; 47: 1049-56.
26. Kurkowska-Jastrzebska I, Wrońska A, Kohutnicka M, Członkowski A, Członkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999; 156: 50-61.
27. Marchetti B, Abbracchio MP. To be or not to be (inflammed) is that the question in anti-inflammatory drug therapy of neurodegenerative diseases? Trends Pharmacol Sci 2005; 26: 517-25.
28. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008; 23: 474-83.
29. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38(8): 1285-91.
30. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Brit J Pharmacol 2007; 150: 963-76.
31. Alvarez-Builla A, Garcia-Verdugo JM, Tramontin AD. A unified hypothesis on the lineage of neural stem cells. Nat Rev Neurosci 2001; 2(4): 287-93.
32. Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999; 97: 703-11.
33. Lledo PM, Alonso M, Grubb MS. Adult neurogenesis and functional plasticity in neuronal circuits. Nature Neurosci 2006; 7: 179-222.
34. Davies JE, Huang C, Proschel C, Noble M, Mayer-Proschel M, Davies SJ. Astrocytes derived from glial-restricted precursors promote spinal cord repair. J Biol 2006; 5:7.
35. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury, J Neurosci 2004; 24: 2143-55.
36. Bélanger M, Magistretti PJ. The role of astroglia in neuroprotection. Dialog. Clin Neurosci 2009; 11(3): 281-95.
37. Blakburn D, Sargsyan S, Monk PN, Shaw PJ. Astrocyte function and role in motor neuron disease: a future therapeutic target? Glia 2009; 57: 1251-64.
38. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW. Proregenerative properties of cytokine-activated astrocytes. J Neurochem 2004; 89: 1092-100.
39. Morale MC, Serra PA, Delogu MR, et al. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J 2004; 18: 164-6.
40. Marchetti B, Serra PA, Tirolo C, et al. Glucocorticoid receptornitric oxide crosstalk and vulnerability to experimental Parkinsonism: pivotal role for glia-neuron interactions. Brain Res Rev 2005; 48(2): 302-21.
41. Marchetti B, Kettenmann H, Streit WJ. Glia-neuron crosstalk in neuroinflammation, neurodegeneration and neuroprotection. Brain Res Review Special Issue 2005; 482(2): 129-489.
42. Kettenmann H, Ransom BR. Neuroglia. Kettenmann H, Ransom BR, eds, Oxford University Press 1995.
43. Mallajosyula JK, Kaur D, Chinta SJ, et al. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One 2008; 3(2): e1616.
44. Gennuso F, Fernetti C, Tirolo C, et al. Bilirubin protects astrocytes from its own toxicity inducing up-regulation and translocation of multigrug resistance-associated protein 1 (Mrp 1). Proc Natl Acad Sci USA 2004; 101: 2470-5.
45. Chen PC, Vargas MR, Pani AK, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci USA 2009; 106(8): 2933-8.
46. Azcoitia I, Garcia-Ovejero D, Chowen JA, Garcia-Segura LM. Astroglia play a key role in the neuroprotective actions of estrogen. Prog Brain Res 2001; 132: 469-78.
47. Garcia-Ovejero D, Veiga S, Garcia-Segura LM, Doncarlos LL. Glial expression of estrogen and androgen receptors after rat brain injury. J Comp Neurol 2002; 450: 256-71.
48. Garcia-Segura LM, Wozniak A, Azcoitia I. Aromatase expression by astrocytes after brain injury: implications for local estrogen formation and brain repair. Neuroscience 1999; 89: 567-78.
49. Engele J, Franke B. Effects of glial cell line-derived neurotrophic factor (GDNF) on dopaminergic neurons require concurrent activation of cAMP-dependent signaling pathways. Cell Tissue Res 1996; 286: 235-40.
50. Engele J, Bohn MC. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia. J Neurosci 1991; 11(10): 3070-8.
51. Gallo F, Morale MC, Spina-Purrello V, et al. Basic fibroblast growth factor (bFGF) acts on both neurons and glia to mediate the neurotrophic effects of astrocytes on LHRH neurons in culture. Synapse 2000; 36: 233-53.
52. Voutilainen MH, Back S, Porsti E, et al. Mesencephalic astrocytederived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009; 29: 9651-9.
53. Castelo-Branco G, Sousa KM, Bryja V, Pinto L, Wagner J, Arenas E. Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol Cell Neurosci 2006; 31(2): 251-62.
54. Gordon MD, Nusse R. Wnt signaling: Multiple pathways, multiple receptors and multiple transcription factors. J Biol Chem 281: 22429-33.
55. L'Episcopo F, Tirolo C, Testa N, et al. Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 2011; 41: 508-27.
56. L'Episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated frizzled-1/β-catenin signalling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegeneration 2011; 6: 49.
57. Horner PJ, Gage FH. Regenerating the damaged central nervous system. Nature 2000; 407(6807): 963-70.
58. Kokaia Z, Lindvall O. Neurogenesis after ischemic brain insults. Curr Opin Neurobiol 2003; 13: 127-32.
59. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human degenerative disorders: How to make it work. Nat Med 2004; 10: S42-50.
60. Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci 2006; 7: 395-406.
61. Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 2003; 100: 7925-30.
62. Shan X, Chi L, Bishop M, et al. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of MPTPinduced Parkinson's disease-like mice. Stem Cells 2006; 24: 1280-1287.
63. Hermann A, Storch A. Endogenous regeneration in Parkinson's disease: Do we need orthotopic dopaminergic neurogenesis? Stem Cells 2008; 26: 2749-52.
64. Butovsky O, Ziv Y, Schwartz A, et al. Microglia activated by IL-4 or IFN-gamma differentiaally induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci 2006; 31: 49-60.
65. Das S, Basu A. Inflammation: a new candidate in modulating adult neurogenesis. J Neurosci Res 2008; 86: 1199-208.
66. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neurosceince 2009; 158: 1021-9.
67. Jakubs K, Bonde S, Iosif RE, et al. Inflammation regulates functional integration of neurons born in adult brain. J Neurosci 2008; 28: 12477-88.
68. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 1760-5.
69. Barkho BZ, Song H, Aimone JB, et al. Identification of astrocyteexpressed factors that modulate neural stem/progenitor cell differentiation. Stem Cells Dev 2006; 15: 407-21.
70. Lim DA, Alvarez-Buylla A. Interaction between astrocytes and adult subventricular zone precursors stimulates neurogenesis. Proc Natl Acad Sci USA 1999; 96: 7526-31.
71. Song H, Stevens CF, Gage FH. Astroglia induce neurogenesis from adult neural stem cells. Nature 2002; 417(6884): 39-44.
72. Hermann A, Maisel M, Wegner F, Liebau S, Kim DW, Gerlach M. Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells 2006; 24: 949-64.